Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Ourania Tatsis Sells 2,350 Shares of Stock

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTXGet Free Report) EVP Ourania Tatsis sold 2,350 shares of the firm’s stock in a transaction dated Thursday, May 30th. The shares were sold at an average price of $439.11, for a total transaction of $1,031,908.50. Following the sale, the executive vice president now directly owns 53,523 shares in the company, valued at approximately $23,502,484.53. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Vertex Pharmaceuticals Stock Up 3.3 %

Shares of VRTX opened at $470.18 on Tuesday. Vertex Pharmaceuticals Incorporated has a 12-month low of $323.02 and a 12-month high of $471.39. The company has a current ratio of 3.50, a quick ratio of 3.29 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $121.33 billion, a PE ratio of 30.51, a price-to-earnings-growth ratio of 2.34 and a beta of 0.41. The business’s 50 day moving average is $418.03 and its 200 day moving average is $410.73.

Vertex Pharmaceuticals (NASDAQ:VRTXGet Free Report) last posted its earnings results on Monday, May 6th. The pharmaceutical company reported $4.76 earnings per share for the quarter, beating the consensus estimate of $3.66 by $1.10. The company had revenue of $2.69 billion during the quarter, compared to analysts’ expectations of $2.58 billion. Vertex Pharmaceuticals had a net margin of 39.46% and a return on equity of 23.08%. Vertex Pharmaceuticals’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period last year, the company posted $2.67 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.22 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vertex Pharmaceuticals

Large investors have recently made changes to their positions in the company. University of Texas Texas AM Investment Managment Co. bought a new stake in Vertex Pharmaceuticals in the 4th quarter worth approximately $25,000. Arlington Trust Co LLC lifted its position in Vertex Pharmaceuticals by 97.1% during the fourth quarter. Arlington Trust Co LLC now owns 67 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 33 shares during the last quarter. Annapolis Financial Services LLC purchased a new position in shares of Vertex Pharmaceuticals in the 1st quarter worth $27,000. ICA Group Wealth Management LLC bought a new stake in shares of Vertex Pharmaceuticals in the 4th quarter worth about $28,000. Finally, Fortitude Family Office LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $30,000. 90.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

VRTX has been the topic of several research analyst reports. Wolfe Research assumed coverage on Vertex Pharmaceuticals in a report on Thursday, February 15th. They set an “outperform” rating and a $515.00 price target on the stock. BMO Capital Markets increased their target price on Vertex Pharmaceuticals from $480.00 to $500.00 and gave the company an “outperform” rating in a report on Friday. downgraded Vertex Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Monday, May 27th. Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 7th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $440.00 target price on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Three research analysts have rated the stock with a sell rating, six have given a hold rating and sixteen have assigned a buy rating to the stock. According to MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $438.62.

Read Our Latest Report on Vertex Pharmaceuticals

About Vertex Pharmaceuticals

(Get Free Report)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Featured Articles

Insider Buying and Selling by Quarter for Vertex Pharmaceuticals (NASDAQ:VRTX)

Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with's FREE daily email newsletter.